Negative symptoms and social cognition as mediators of the relationship between neurocognition and functional outcome in schizophrenia
- PMID: 38356912
- PMCID: PMC10864497
- DOI: 10.3389/fpsyt.2024.1333711
Negative symptoms and social cognition as mediators of the relationship between neurocognition and functional outcome in schizophrenia
Abstract
Introduction: In this study we assessed the contribution of psychopathology, including the two domains of negative symptoms (motivational deficit and expressive deficit), processing speed as an index of neurocognition, and emotion recognition, as an index of social cognition, to poor functional outcomes in people with schizophrenia.
Methods: The Positive and Negative Syndrome Scale was used to evaluate positive symptoms and disorganization and the Brief Negative Symptom Scale to assess negative symptoms. The Symbol Coding and the Trail Making Test A and B were used to rate processing speed and the Facial Emotion Identification Test to assess emotion recognition. Functional outcome was assessed with the Personal and Social Performance Scale (PSP). Regression analyses were performed to identify predictors of functional outcome. Mediation analyses was used to investigate whether social cognition and negative symptom domains fully or partially mediated the impact of processing speed on functional outcome.
Results: One hundred and fifty subjects from 8 different European centers were recruited. Our data showed that the expressive deficit predicted global functioning and together with motivational deficit fully mediated the effects of neurocognition on it. Motivational deficit was a predictor of personal and social functioning and fully mediated neurocognitive impairment effects on the same outcome. Both motivational deficit and neurocognitive impairment predicted socially useful activities, and the emotion recognition domain of social cognition partially mediated the impact of neurocognitive deficits on this outcome.
Conclusions: Our results indicate that pathways to functional outcomes are specific for different domains of real-life functioning and that negative symptoms and social cognition mediate the impact of neurocognitive deficits on different domains of functioning. Our results suggest that both negative symptoms and social cognition should be targeted by psychosocial interventions to enhance the functional impact of neurocognitive remediation.
Keywords: emotion recognition; expressive deficit; mediation analysis; motivational deficit; negative symptoms; processing speed; schizophrenia.
Copyright © 2024 Giordano, Pezzella, Mucci, Austin, Erfurth, Glenthøj, Hofer, Hubenak, Libiger, Melle, Nielsen, Rybakowski, Wojciak, Galderisi and Sachs.
Conflict of interest statement
GG has been a consultant for Angelini. AM has been a consultant and/or advisor to or has received honoraria from Angelini, Gedeon. Richter Bulgaria, Janssen Pharmaceuticals, Lundbeck, Otsuka Pharmaceutical, Pfizer, Pierre Fabre, Rovi. Pharma and Boehringer Ingelheim. AE received consulting fees and/or honoraria for speeches within the last 3 years from Angelini, AOP Orphan, Germania, Janssen, Krka, Lundbeck, Mylan, Neuraxpharm, Recordati, and Sandoz. BG has been the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research CINS January 2009 – December 2021, which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administrated by them. She has no other conflicts to disclose. AH has been a consultant for Recordati and Boehringer Ingelheim and Newron Pharmaceuticals and participated in educational conferences for Janssen and Lundbeck. JH received consulting fees and/or honoraria for speeches within the last 3 years from Angelini, Lundbeck, Janssen and Servier. SG has been a consultant and/or advisor to or has received honoraria from Angelini, Boehringer Ingelheim, Gedeon Richter-Recordati, Innova Pharma-Recordati Group, Janssen, Lundbeck, Otsuka, Recordati Pharmaceuticals, Rovi Pharma and Sunovion Pharmaceuticals. GS is president of the Austrian Society of Neuropsychopharmacology and Biological Psychiatry, which is partially financed by the support from pharmaceutical companies. GS received consulting fees and/or honoraria for speeches within the last 3 years from Janssen, Lundbeck, Mylan, Recordati, and Schwabe. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer CM declared a past co-authorship with the authors AM and SG to the handling editor. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Figures



Similar articles
-
Expressive deficits and amotivation as mediators of the associations between cognitive problems and functional outcomes: Results from two independent cohorts.Schizophr Res. 2020 Apr;218:283-291. doi: 10.1016/j.schres.2019.12.018. Epub 2020 Jan 13. Schizophr Res. 2020. PMID: 31948899
-
Improving Knowledge on Pathways to Functional Outcome in Schizophrenia: Main Results From the Italian Network for Research on Psychoses.Front Psychiatry. 2021 Dec 14;12:791117. doi: 10.3389/fpsyt.2021.791117. eCollection 2021. Front Psychiatry. 2021. PMID: 34970172 Free PMC article. Review.
-
Neurocognition and symptoms identify links between facial recognition and emotion processing in schizophrenia: meta-analytic findings.Schizophr Res. 2013 Dec;151(1-3):78-84. doi: 10.1016/j.schres.2013.10.015. Epub 2013 Nov 21. Schizophr Res. 2013. PMID: 24268469 Free PMC article. Review.
-
The relationship between negative symptoms and MATRICS neurocognitive domains: A meta-analysis and systematic review.Prog Neuropsychopharmacol Biol Psychiatry. 2023 Dec 20;127:110833. doi: 10.1016/j.pnpbp.2023.110833. Epub 2023 Jul 22. Prog Neuropsychopharmacol Biol Psychiatry. 2023. PMID: 37482283
-
Interplay among positive and negative symptoms, neurocognition, social cognition, and functioning in clinically stable patients with schizophrenia: a network analysis.F1000Res. 2021 Dec 8;10:1258. doi: 10.12688/f1000research.74385.3. eCollection 2021. F1000Res. 2021. PMID: 35464178 Free PMC article.
Cited by
-
Effectiveness of a social cognition remediation intervention for patients with schizophrenia: a randomized-controlled study.Ann Gen Psychiatry. 2024 Dec 28;23(1):52. doi: 10.1186/s12991-024-00535-9. Ann Gen Psychiatry. 2024. PMID: 39732701 Free PMC article.
-
Understanding suicidality in adolescents and young adults at clinical high risk for psychosis: a narrative review on risk factors and clinical insights.Front Psychiatry. 2025 Jun 19;16:1580646. doi: 10.3389/fpsyt.2025.1580646. eCollection 2025. Front Psychiatry. 2025. PMID: 40612032 Free PMC article. Review.
-
Analysis of the status quo and clinical influencing factors of the social cognitive impairment in deficit schizophrenia.Front Psychiatry. 2024 Oct 2;15:1470159. doi: 10.3389/fpsyt.2024.1470159. eCollection 2024. Front Psychiatry. 2024. PMID: 39415884 Free PMC article.
-
Relationship between cognitive reserve (education), social cognition and negative symptoms.Schizophr Res Cogn. 2025 Jul 21;42:100379. doi: 10.1016/j.scog.2025.100379. eCollection 2025 Dec. Schizophr Res Cogn. 2025. PMID: 40726499 Free PMC article.
-
How do negative symptoms and social cognitive impairments overlap? Clustering analyses on patients living with schizophrenia-spectrum disorder.Soc Cogn Affect Neurosci. 2025 Jan 18;20(1):nsaf061. doi: 10.1093/scan/nsaf061. Soc Cogn Affect Neurosci. 2025. PMID: 40576457 Free PMC article.
References
-
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (London England) (2017) 390(10100):1211–59. doi: 10.1016/S0140-6736(17)32154-2 - DOI - PMC - PubMed
-
- Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. . Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry (2022) 21(2):248–71. doi: 10.1002/wps.20994 - DOI - PMC - PubMed
-
- Galderisi S, Rucci P, Kirkpatrick B, Mucci A, Gibertoni D, Rocca P, et al. . Interplay among psychopathologic variables, personal resources, context-related factors, and real-life functioning in individuals with schizophrenia: A network analysis. JAMA Psychiatry (2018) 75(4):396–404. doi: 10.1001/jamapsychiatry.2017.4607 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous